A randomized, multi-center, open-label study to compare the safety and efficacy between afatinib monotherapy and combination therapy of afatinib and HAD-B1 for the locally advanced or metastatic NSCLC patients with EGFR mutations: Erratum

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Erratum
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8758016/
https://www.ncbi.nlm.nih.gov/pubmed/35029238
http://dx.doi.org/10.1097/MD.0000000000028585

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8758016/
https://www.ncbi.nlm.nih.gov/pubmed/35029238
http://dx.doi.org/10.1097/MD.0000000000028585

Ejemplares similares